Provided by Tiger Fintech (Singapore) Pte. Ltd.

Teva Pharmaceutical

16.48
+0.38002.36%
Post-market: 16.480.0001+0.00%19:41 EDT
Volume:16.47M
Turnover:270.84M
Market Cap:18.88B
PE:-11.37
High:16.71
Open:16.22
Low:16.05
Close:16.10
Loading ...

Teva Pharmaceutical Industries (TEVA) Reports Q3 Earnings: What Key Metrics Have to Say

Zacks
·
06 Nov 2024

Teva Pharm CEO Francis Says We Think We Have a "Good Case" in Appeal Against European Commission Fine, Appeal Likely to Take Many Years

THOMSON REUTERS
·
06 Nov 2024

Teva Pharm CEO Francis Says Divestment of Teva API on Target for First Half of 2025

THOMSON REUTERS
·
06 Nov 2024

Teva Pharm CEO Francis Says We Are Driving Strong Performance Due to Our Branded Drugs

THOMSON REUTERS
·
06 Nov 2024

Teva Pharm CEO Francis Says Expects Generics Prices to Be Pushed Down in 2025

THOMSON REUTERS
·
06 Nov 2024

Teva Pharm CEO Francis Says on Track to Meet Growth Targets by 2027 of Revenue Growth, Operating Margin and Net Debt/Ebitda

THOMSON REUTERS
·
06 Nov 2024

Teva Pharmaceutical Q3 Non-GAAP Earnings, Net Revenue Rise; 2024 Outlook Updated

MT Newswires Live
·
06 Nov 2024

BRIEF-Teva Reports Q3 2024 Results, Driven By Generics And Innovative Portfolio, Raises 2024 Outlook

Reuters
·
06 Nov 2024

Teva Forecasts 2024 Revenues Of $16.1B-$16.5B Versus Prior Guidance Of $16.0B-$16.4B And Consensus Of $16.256B

Benzinga
·
06 Nov 2024

Teva Forecasts 2024 Adjusted EPS Of $2.40-$2.50 Versus Prior Guidance Of $2.30-$2.50 And Consensus Of $2.45

Benzinga
·
06 Nov 2024

Teva Pharmaceutical beats Q3 top and bottom line estimates, raises outlook

seekingalpha
·
06 Nov 2024

Teva Pharmaceutical Indus Q3 2024 Adj EPS $0.69 Beats $0.66 Estimate, Sales $4.33B Beat $4.12B Estimate

Benzinga
·
06 Nov 2024

Teva Announces Strong Financial Results for the Third Quarter of 2024, Led by Generics Performance and Innovative Portfolio Growth; Raises 2024 Financial Outlook Including on Revenues, Adjusted Ebitda and Non-Gaap EPS

THOMSON REUTERS
·
06 Nov 2024

Teva Announces Strong Financial Results for the Third Quarter of 2024, led by Generics Performance and Innovative Portfolio Growth; Raises 2024 Financial Outlook including on Revenues, Adjusted EBITDA and Non-GAAP EPS

GlobeNewswire
·
06 Nov 2024

Barclays Reaffirms Their Buy Rating on Teva Pharmaceutical (TEVA)

TIPRANKS
·
06 Nov 2024

Here's the major earnings before the open tomorrow

seekingalpha
·
06 Nov 2024